“International Medical Service in Egypt.”

(Anti-MCV) New reliable immunological marker for diagnosis & prognosis of rheumatoid arthritis

Mutated Citrullinated Vimentin, MCV, is involved in the pathogenic pathways leading to rheumatoid arthritis. It has been proven to play a crucial role in triggering Anti-citrullinated peptide antibodies, ACPA, production. Its presence in immune complexes from RA synovial fluid further illustrates the pathological impact of this protein in Rheumatoid Arthritis.

ACPA have been considered as the most specific known serum markers for rheumatoid arthritis (RA). They include anti-mutated citrullinated vimentin ( anti-MCV ) and anti-cyclic citrullinated peptide antibodies, (anti-CCP). They have been detected in RF-Negative individuals. In contrast to CCP, the MCV antigen is an entire native protein. It contains at least 10 known citrullination sites and displays a greater number of different epitopes implying an increased sensitivity of anti-MCV to bind a variety of auto antibodies.

As ACPA develop several years before the first clinical manifestations of arthritis, quantitation of anti MCV antibodies in sera is highly predictive of progression from undifferentiated arthritis to definite RA, as shown in several longitudinal cohort studies of patients with early undifferentiated arthritis. ACPA has been introduced among the criteria of the "2010 American College of Rheumatology/European League Against Rheumatism" for persistent, non erosive polyarthritis requiring methotrexate therapy. The test requires 1 ml serum and the result can be obtained within less than one week. (Anti-MCV) is now routinely done in ALFA LABORATORIES

 

joomla wellnessLorem Ipsum has been the industry's standard dummy text ever since the 1500s...